Upfront Surgery Versus Definitive Radiotherapy: Competing Risk Analyses in Early Stage Oropharyngeal Cancer
Otolaryngology–Head and Neck Surgery · 2023
DOI: 10.1002/ohn.245 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2023. Verfasst von Liang Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Oropharyngeal Neoplasms, Head and Neck Neoplasms. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare the survival outcomes of early‐stage oropharyngeal cancer (OPC) patients treated with upfront surgery versus definitive radiotherapy (RT). Study Design Retrospective observational study.
Setting
Publicly available database.
Methods
A total of 1877 patients with T1‐2N0‐1M0 OPC were retrieved from the Surveillance, Epidemiology, and End Results database. Primary endpoints were cancer‐specific and noncancer mortalities, which were estimated using cumulative incidence function and compared by Gray's test. Univariate and multivariate Fine‐Gray subdistribution hazard models were used to estimate the effects of treatment modality on mortality. Subgroup analyses were performed in propensity‐score‐matched cohorts. All the analyses were conducted separately in human papillomavirus (HPV)‐negative and HPV‐positive cohorts.
Results
In the HPV‐negative cohort, definitive RT was independently associated with increased risk of cancer‐specific mortality (adjusted subdistribution hazard ratio [SHR], 2.29; 95% confidence interval [CI], 1.42‐3.68; p = .001) and noncancer mortality (adjusted SHR, 2.74; 95% CI, 1.50‐5.02; p = .001). In the HPV‐positive cohort, definitive RT and upfront surgery could achieve similar cancer‐specific and noncancer survival outcomes.
Conclusion
Upfront surgery is associated with lower cancer‐specific and noncancer mortality in HPV‐negative early‐stage OPC patients. However, in the setting of HPV‐positive early‐stage OPC with better prognosis, the 2 treatment modalities have similar efficacy in terms of cancer‐specific and noncancer survival outcomes. In the future, carefully designed prospective clinical trials are needed to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Institute of Otolaryngology-Head and Neck Surgery, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Otolaryngology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong, Guangzhou, China.
Zitieren
APA
Peng, L., Zeng, X. L., Fang, R. H., Ma, R. Q., Wen, W. P., & Sun, W. (2023). Upfront Surgery Versus Definitive Radiotherapy: Competing Risk Analyses in Early Stage Oropharyngeal Cancer. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.245
Vancouver
Peng L, Zeng XL, Fang RH, Ma RQ, Wen WP, Sun W. Upfront Surgery Versus Definitive Radiotherapy: Competing Risk Analyses in Early Stage Oropharyngeal Cancer. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.245
BibTeX
@article{Peng2023,
author = {Peng, Liang and Zeng, Xue-Lan and Fang, Rui-Hua and Ma, Ren-Qiang and Wen, Wei-Ping and Sun, Wei},
title = {Upfront Surgery Versus Definitive Radiotherapy: Competing Risk Analyses in Early Stage Oropharyngeal Cancer},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
doi = {10.1002/ohn.245}
}
EUVIMED